The transition from conventional software-only artificial intelligence to physical AI systems incor- porating robotic hardware in oncology clinical trials represents a paradigm shift requiring unified infrastructure for privacy, regulation, cross-framework interoperability, and multi-organization coop- eration. This paper presents the PAI Oncology Trial FL platform (v1.1.0), a comprehensive federated learning framework comprising 235 Python modules (∼86,800 lines of code) that unifies five critical infrastructure pillars: (1) Privacy Infrastructure implementing all 18 HIPAA Safe Harbor identifiers with HMAC-SHA256 pseudonymization, (2) Regulatory Infrastructure spanning FDA, IRB, ICH- GCP, and multi-jurisdiction compliance across v0.6.0 and v0.9.1, (3) Cross-Framework Unification bridging NVIDIA Isaac Sim, MuJoCo, Gazebo, and PyBullet simulation environments, (4) Stan- dards & Benchmarking for Q1 2026 objectives including model conversion and registry pipelines, and (5) Multi-Organization Cooperation enabling federated training across academic medical cen- ters, community hospitals, and pharmaceutical companies. End-to-end workflow demonstrations are presented across 31 example scripts, 6 agentic AI production examples implementing Model Context Protocol (MCP), ReAct reasoning, real-time monitoring, autonomous orchestration, safety- constrained execution, and RAG-based compliance. A triple AI peer review process (v0.9.4–v0.9.9) using sequential Codex-to-Claude Code review-fix cycles resolved 31/31 code recommendations at 100% completion, establishing a dual-manufacturer trust benchmark for AI-generated clinical trial software. The platform demonstrates that unified federated learning infrastructure is a necessary precondition for transitioning the oncology industry to using robots in physical AI clinical trials.
Building similarity graph...
Analyzing shared references across papers
Loading...
Kevin Kawchak
Building similarity graph...
Analyzing shared references across papers
Loading...
Kevin Kawchak (Fri,) studied this question.
synapsesocial.com/papers/69a3d8b8ec16d51705d2fd5e — DOI: https://doi.org/10.5281/zenodo.18795507